The global medical nonwoven fabric market continues its rapid expansion, driven by sustained demand for single-use infection-control products, advanced wound care, and personal protective equipment. Among all nonwoven manufacturing technologies, spunlace (hydroentanglement) has emerged as the preferred method for medical-grade fabrics because it delivers a unique combination of softness, structural integrity, lint-free surfaces, and biocompatibility — without relying on any chemical binders or adhesives.
This article provides a comprehensive technical overview of spunlace nonwoven fabric for medical use, covering the manufacturing process, critical fiber engineering choices, key performance parameters, application scope, sterilization compatibility, and regulatory considerations. All product references draw on the full product range from Zhejiang Aojia Nonwoven Technology Co., Ltd., a specialist manufacturer of spunlace nonwoven fabrics for global healthcare and hygiene markets.
Spunlace nonwoven fabric — also referred to as hydroentangled nonwoven — is produced by directing precisely controlled, high-pressure water jets (typically 50 to 400 bar) onto a loosely formed web of fibers laid on a moving conveyor. The water jets cause individual fibers to mechanically interlock and entangle with their neighbors, creating a unified fabric structure without any chemical binders, thermal bonding agents, or adhesives.
This binder-free architecture is the defining technical advantage of spunlace for medical applications. The absence of chemical additives directly reduces the risk of skin sensitization and extractable/leachable substance contamination in clinical environments — a critical consideration for wound contact and patient-facing products.
The performance profile of any medical spunlace fabric is dictated first by fiber selection and blend ratio. Different clinical applications impose fundamentally different performance requirements, making fiber engineering the starting point for any new medical product development.
The most widely adopted blend for wound care substrates is the 70% viscose / 30% polyester (70% Vis / 30% PET) combination, as used in Aojia's wound dressing fabric. Here is why this ratio dominates:
Viscose (regenerated cellulose) contributes high hydrophilicity — absorbing wound exudate rapidly and maintaining the moist wound environment that modern wound care science recognizes as optimal for epithelialization. Polyester fibers, being hydrophobic and dimensionally stable, reinforce wet tensile strength and burst resistance, preventing dressing disintegration during exudate saturation or removal.
For face mask cloth, 100% polyester spunlace is the technical preference. Polyester's very low moisture regain (0.4%) keeps fiber geometry stable under humid respiratory conditions, preserving both filtration efficiency and breathing comfort throughout extended wear. Its inherent hydrophobicity also reduces liquid wicking through the mask layers — a key infection-control attribute.
Medical-grade spunlace fabrics from Aojia's medical series typically span 40 to 60 g/m². Lower GSM (40–45 g/m²) produces lightweight, highly breathable constructions suited to mask inner layers and thin wound contact films. Higher GSM (50–60 g/m²) increases both absorbent capacity and structural bulk, making it appropriate for primary wound dressings where exudate management volume is significant.
Width flexibility determines how efficiently industrial converters can process rolls into finished products. Aojia's wound dressing fabric is available from 100 mm to 3,200 mm, accommodating everything from narrow adhesive bandage strips to wide-format surgical drape blanks. The face mask cloth ranges from 145 mm to 3,300 mm, suitable for high-speed rotary die-cutting converting lines.
These two mechanical parameters are the primary pass/fail criteria for wound care substrates in clinical quality-control protocols. Wet tensile strength governs structural integrity during removal from a moist wound bed — a critical patient safety parameter, since fragmentation leaves fiber residue embedded in healing tissue. Burst strength determines resistance to hydrostatic pressure relevant for dressings placed under compression bandaging systems.
Aojia manufactures medical spunlace in both plain and mesh surface structures. Plain fabric provides a smooth, uniform contact interface that minimizes mechanical irritation at wound or skin interfaces. Mesh-structured fabric features an open, grid-like pattern that creates fluid drainage channels and promotes air circulation — particularly advantageous in highly exudating wounds where maceration prevention is a clinical priority. Selection between these structures is an engineering decision driven by the specific clinical end-use.
Primary contact layers, adhesive bandages, IV securement dressings, ECG electrode pads, and transdermal drug delivery patch substrates. The 70/30 viscose-PET blend delivers the absorbency-to-strength ratio wound care engineers require.
Inner comfort layer or outer structural layer in multi-layer disposable mask constructions. 100% polyester spunlace maintains low breathing resistance and shape retention under humid respiratory conditions.
Substrate materials for composite medical laminates, coated specialty fabrics, and sterile packaging materials. The base cloth series leverages the same hydroentanglement platform for multi-layer constructions.
The wipes series applies the same hydroentanglement technology to produce clinical disinfection and surface-wiping products. Low linting and high wet strength make spunlace the preferred substrate for impregnated hospital wipes.
Beyond these core categories, the broader Aojia product range addresses surgical drapes, isolation gowns, sterile packaging substrates, and adjacent hygiene applications. The common thread across all these uses is the hydroentanglement platform's ability to deliver controlled porosity, consistent surface texture, and confirmed biocompatibility at scale.
Medical spunlace fabrics must withstand the standard industrial sterilization methods used across the healthcare supply chain. The viscose/polyester and 100% polyester constructions that form the core of Aojia's medical product line are engineered to maintain dimensional stability, tensile integrity, and surface morphology after exposure to all three principal methods: ethylene oxide (EtO) gas sterilization, gamma irradiation, and electron beam (E-beam) processing.
The binder-free hydroentanglement structure provides an inherent advantage here. Without chemical adhesives or thermoplastic binder fibers, there is no bonding matrix susceptible to chemical attack by EtO or degradation from ionizing radiation — a failure mode that affects some thermally bonded nonwovens at typical irradiation doses (15–25 kGy for gamma sterilization).
Medical textiles are subject to rigorous regulatory frameworks across major global markets. In wound care, fabrics used as primary dressing components must demonstrate biocompatibility per ISO 10993 — a multi-part standard covering cytotoxicity, sensitization, and genotoxicity testing. For surgical environment products (drapes, gowns), EN 13795 sets performance thresholds for linting, microbial penetration, and tensile properties. Face masks incorporating spunlace layers must meet EN 14683 (Type I / II / IIR) for bacterial filtration efficiency and breathing resistance.
The binder-free nature of spunlace construction provides a regulatory advantage: without chemical additives, extractables and leachables testing (required under ISO 10993-12 and 10993-18) is substantially simplified, reducing both testing time and compliance cost for medical device converters sourcing fabric from Aojia.
FDA Note: Wound dressings containing spunlace fabric substrates may qualify as Class I or Class II medical devices in the United States, with applicable 510(k) premarket notification pathways. Material biocompatibility data from the fabric manufacturer forms a critical component of device technical files.
